News | December 09, 2023
Fire accident at Parmax Pharma’s plant
There has been no loss or injury to human life
There has been no loss or injury to human life
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
India had proposed for setting up the global standards for millets
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Almost 300 million people globally have chronic hepatitis B
Final stage in licensing OVM-200 from Oxford Vacmedix in the UK
The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care
First-in-class AKT inhibitor has potential to reshape treatment for breast cancer patients
The product will be manufactured at Lupin’s Nagpur facility in India
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
